{
    "clinical_study": {
        "@rank": "80548", 
        "arm_group": {
            "arm_group_label": "Cohort"
        }, 
        "brief_summary": {
            "textblock": "This prospective observational study will evaluate the safety and efficacy of first-line\n      Avastin (bevacizumab) in combination with standard chemotherapy in routine clinical practice\n      in patients with metastatic cancer of the colon and/or rectum. Patients will be followed for\n      the duration of their treatment and a 30-day follow-up after the last dose of study drug."
        }, 
        "brief_title": "An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Cancer of the Colon or Rectum", 
        "completion_date": {
            "#text": "August 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Colorectal Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Colonic Neoplasms", 
                "Colorectal Neoplasms", 
                "Neoplasm Metastasis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adult patients, >/= 18 years of age\n\n          -  Histologically or cytologically confirmed carcinoma of the colon and/or rectum with\n             evidence of metastases\n\n          -  At least one measurable metastatic lesion (as per RECIST criteria)\n\n          -  Life expectancy of > 12 weeks\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-2\n\n          -  Adequate hematological, renal and liver function\n\n        Exclusion Criteria:\n\n          -  Prior chemotherapy for metastatic disease\n\n          -  Clinically significant cardiovascular disease\n\n          -  Ongoing treatment with aspirin (325 mg/day) or other medications known to predispose\n             for gastrointestinal ulceration\n\n          -  Participation in an investigational trial in the previous 3 months\n\n          -  Pregnant or lactating women\n\n          -  History of thrombotic or haemorrhagic disorders\n\n          -  Evidence of bleeding diathesis or coagulopathy\n\n          -  Uncontrolled hypertension\n\n          -  Known hypersensitivity to Avastin and any of its excipients, or any of the\n             chemotherapies\n\n          -  Evidence of any disease or disorder that contraindicates the use of an\n             investigational drug or puts the patient at high risk for treatment-related\n             complications"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Patients with metastatic cancer of the colon and/or rectum"
            }
        }, 
        "enrollment": {
            "#text": "35", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 10, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01830647", 
            "org_study_id": "ML28411"
        }, 
        "intervention_browse": {
            "mesh_term": "Bevacizumab"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 5, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Podgorica", 
                    "country": "Montenegro", 
                    "zip": "81000"
                }
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Montenegro"
        }, 
        "number_of_groups": "1", 
        "official_title": "Non-interventional Local Study to Describe the Safety, Tolerability and Efficacy of Bevacizumab in Combination With Standard Chemotherapy Regimens as First Line in Patients With Metastatic Cancer of the Colon or the Rectum", 
        "overall_contact": {
            "email": "global.rochegenentechtrials@roche.com", 
            "last_name": "Reference Study ID Number: ML28411 www.roche.com/about_roche/roche_worldwide.htm", 
            "phone": "888-662-6728 (U.S. Only)"
        }, 
        "overall_official": {
            "affiliation": "Hoffmann-La Roche", 
            "last_name": "Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Montenegro: Agency for Medicines and Medical Devices of Montenegro"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "August 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Safety: Incidence of adverse events", 
            "safety_issue": "No", 
            "time_frame": "approximately 3.5 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01830647"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Efficacy: Time to disease progression", 
            "safety_issue": "No", 
            "time_frame": "approximately 3.5 years"
        }, 
        "source": "Hoffmann-La Roche", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hoffmann-La Roche", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}